Similarities and Differences Between Botox, Dysport and Xeomin

Coke and Pepsi is a good analogy when thinking about the three neurotoxins now available on the market – Botox, Dysport and Xeomin.


Similarities and Differences Between Botox, Dysport and Xeomin

Coke and Pepsi is a good analogy when thinking about the three neurotoxins now available on the market – Botox, Dysport and Xeomin.

Despite many patient and physicians perceptions which can be found all over the web, the 3 neuromodulators are much more similar than dissimilar. They all have the same 150 kDa molecule at their core, and very similar onset, efficacy and duration.

Some experts believe that Dysport may have a faster onset, but we don’t have a good head-to-head clinical trial to prove it. Others claim that Dysport may diffuse (spread) more than Botox, but this also has yet to be proven in a substantial clinical trial. The spread of the product appears to actually be related to how the product is mixed an injected, rather than the actual product itself.

All 3 neurotoxins are extremely safe. Ptosis (brow drop) is the main adverse event patients are concerned with, and both Dysport and Botox had ptosis occur in 3% of patients during FDA phase 3 trials.

Botox, made by Allergan, is part of the Brilliant Distinctions rewards program. Dysport, made by Medicis, has their Love It or Money Back guarantee program.

The unit-to-unit equivalents and dilution ratios are the same for Botox and Xeomin, but different for Dysport (which is why it is often hard to compare prices). At the moment Dysport is usually slightly less expensive for the patient than Botox. We have yet to see what Xeomin will be priced at and how it will affect this competitive arena. The one positive we see already with Xeomin is that it does not require refrigeration.

Neurotoxin injections totaled 5.4 million dollars in 2010 alone, so there does seem to be enough space to support the 3 brands. There is even another neurotoxin on the horizon, called PurTox, which is currently in clinical trials and may become available over the next few years.

Ultimately it comes down to brand recognition and marketing. As Botox was the first to come to market and spent millions on direct-to-consumer advertising, most patients come in asking for it by name. Dysport has not spent nearly the same amount in marketing dollars and is much newer than Botox, so is still much less known to the general public. Xeomin was only FDA approved a few weeks ago, so we will have to wait and see what they do in terms of marketing.

For now, the most important aspect of getting a good result is to go to an expert injector who knows how to dilute the product, where to place it, and how much to put where.

 

 

310-657-2203
Babak Azizzadeh, M.D., F.A.C.S.
9401 Wilshire Blvd, Suite 650 Beverly Hills, California 90212
E-mail us: info@facialplastics.info